GlassScriptPhysician profile
Michael Roy Lyles
NPI 1861567208
$3,233.28
in general payments reported to CMS, 2019-2025
16 companies · $678 in 2025
The $678 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $60.61 · 2021: $15.90 · 2022: $462 · 2023: $1,212 · 2024: $639 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,529.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $843.91 | 2022-2025 | Qelbree, Qelbree |
| Abbvie INC. | $594.39 | 2021-2024 | |
| Axsome Therapeutics, INC. | $465.25 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $422.94 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $234.58 | 2022-2025 | Trintellix |
| Lundbeck LLC | $209.88 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.29 | 2022-2023 | |
| Almatica Pharma LLC | $85.27 | 2024-2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $75.50 | 2020-2023 | Spravato |
| Allergan, INC. | $43.28 | 2020 | |
| Bausch Health US, LLC | $41.48 | 2022 | |
| Idorsia Pharmaceuticals US INC | $29.82 | 2023-2024 | Quviviq |
| Jazz Pharmaceuticals INC. | $21.69 | 2019 | |
| Merck Sharp & Dohme LLC | $20.67 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.30 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $14.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lyles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.